Aragon-Ching Jeanny B, Dahut William L
Division of Hematology/Oncology, George Washington University Medical Center, Washington, DC, USA.
Drug Discov Today Ther Strateg. 2010 Jul 1;7(1-2):31-35. doi: 10.1016/j.ddstr.2011.02.004.
Androgen deprivation therapy has been the mainstay of treatment for advanced and metastatic prostate cancer. The use of novel agents targeting the androgen receptor and its signaling pathways offers a promising approach that is both safe and effective. We describe the rationale behind the use of these compounds in clinical development and the existing challenges as to how best to incorporate these new and emerging therapies in the changing treatment paradigm of metastatic prostate cancer.
雄激素剥夺疗法一直是晚期和转移性前列腺癌的主要治疗方法。使用靶向雄激素受体及其信号通路的新型药物提供了一种既安全又有效的有前景的方法。我们描述了这些化合物在临床开发中使用的基本原理，以及在转移性前列腺癌不断变化的治疗模式中如何最好地纳入这些新出现的疗法所面临的现有挑战。
